Weight loss is linked to decreased risk of colon and rectal polyps

Share This Post

May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5 pounds over five years have a 46 percent lower risk of developing precancerous colon polyps, which are benign growths in the colon or rectum that can lead to colorectal cancer.

Body weight and colon cancer

From 1993 to 2001, researchers examined the relationship between weight change and colon and rectal polyps in 18,588 men and women who took part in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening study. People who have self-reported their weight three times during the course of their lives were included in the study. The case group included 1,053 people who acquired polyps three to five years into the study, while the control group included those who did not. Those who dropped weight throughout early to late adulthood had a much lower risk of having polyps than those who maintained their weight, especially if they were initially overweight (had a BMI of more than 25). People who gained weight during the trial, on the other hand, had a 1.3 times higher risk of getting polyps. In comparison to women, the link appeared to be stronger in men.

Researchers have discovered for the first time that limiting weight gain during adulthood lowers the risk of acquiring precancerous growths that can lead to colorectal cancer. The advantages appear to be linked to being overweight or obese.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy